Business Context and Reporting Period
This Form 8-K Current Report from Entrada Therapeutics, Inc. (TRDA) covers events occurring on June 13, 2024, specifically the Company's 2024 Annual Meeting of Stockholders. The meeting was conducted in a virtual-only format. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Voting Results
Stockholders approved three key proposals at the Annual Meeting. As of the record date (April 16, 2024), there were 33,677,918 shares outstanding, with 22,221,263 shares present or represented by proxy, establishing a quorum.
- Proposal No. 1 (Director Election): Gina Chapman was elected as a Class III director to serve until the 2027 annual meeting.
- For: 19,701,297
- Withheld: 101,960
- Broker Non-Votes: 2,418,006
- Proposal No. 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- For: 22,210,935
- Against: 2,174
- Abstain: 8,154
- Proposal No. 3 (Certificate of Amendment): Stockholders approved an amendment to the Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law. The amendment became effective upon filing with the Delaware Secretary of State on June 13, 2024.
- For: 18,354,494
- Against: 1,446,761
- Abstain: 2,002
- Broker Non-Votes: 2,418,006
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, or specific risk factors beyond the standard disclosure that the description of the Certificate of Amendment is qualified by reference to the full text filed as Exhibit 3.1. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the full text of the Certificate of Amendment (Exhibit 3.1) to understand the specific scope of officer liability limitations.
- Confirm the tenure and responsibilities of the newly elected director, Gina Chapman.
- Review the definitive Proxy Statement filed on April 29, 2024, for detailed background on the proposals and governance context.
- Note that this filing does not update the Company's financial position; refer to the most recent 10-K or 10-Q for financial health metrics.